DeepMed Research

National Eye Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1968-01-01

Employees: 101

Market Cap: -

Website: http://www.nei.nih.gov

Clinical Trials

Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss

Not Applicable

Active, not recruiting

Conditions: Central Vision Loss From Macular Diseases

First Posted Date: 2024-11-01

Last Posted Date: 2024-11-01

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 30

Registration Number: NCT06670989

Locations: 🇺🇸
Herbert Wertheim School of Optometry & Vision Science, University of California Berkeley, Berkeley, California, United States

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

Recruiting

Conditions: Hypopigmentation Disorder
Aniridia
Inherited Ophthalmic Diseases
Blue-cone Monochromacy
Albinism
Corneal Dystrophy
Best Disease

First Posted Date: 2024-07-09

Last Posted Date: 2025-04-23

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 1000

Registration Number: NCT06491615

Locations: 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Potential Environmental Causes of Uveal Coloboma

Completed

Conditions: Coloboma

First Posted Date: 2021-04-06

Last Posted Date: 2025-04-23

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 76

Registration Number: NCT04833361

Locations: 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States

Microbiome as a ThErapeutic Response Biomarker

Withdrawn

Conditions: Uveitis

First Posted Date: 2021-01-25

Last Posted Date: 2021-05-06

Lead Sponsor: National Eye Institute (NEI)

Registration Number: NCT04721743

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Biomarkers in Ocular Inflammation and Uveitis

Completed

Conditions: Uveitis
Ocular Inflammation

First Posted Date: 2020-12-31

Last Posted Date: 2024-04-17

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 69

Registration Number: NCT04690829

Locations: 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States

Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors

Terminated

Conditions: COVID-19

First Posted Date: 2020-12-14

Last Posted Date: 2022-10-06

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 8

Registration Number: NCT04665752

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Recruiting

Conditions: Stargardt-Like Macular Dystrophy

First Posted Date: 2020-10-19

Last Posted Date: 2025-04-17

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 25

Registration Number: NCT04591483

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Oral Metformin for Treatment of ABCA4 Retinopathy

Phase 1

Recruiting

Conditions: Stargardt Disease
ABCA4 Retinopathy
Retinal Dystrophy
Retinal Degeneration

Interventions: Drug: Metformin hydrochloride

First Posted Date: 2020-09-11

Last Posted Date: 2025-04-23

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 56

Registration Number: NCT04545736

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma

Active, not recruiting

Conditions: Retinal Hemangioblastoma
Von Hippel-Lindau Disease

First Posted Date: 2020-07-07

Last Posted Date: 2025-03-18

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 25

Registration Number: NCT04458935

Locations: 🇺🇸
National Eye Institute (NEI), Bethesda, Maryland, United States

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Phase 1

Recruiting

Conditions: Dry Age-Related Macular Degeneration
Geographic Atrophy

Interventions: Drug: iPSC-derived RPE/PLGA transplantation

First Posted Date: 2020-04-09

Last Posted Date: 2025-04-27

Lead Sponsor: National Eye Institute (NEI)

Target Recruit Count: 20

Registration Number: NCT04339764

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy